

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound comprising a bifunctional fusion glycoprotein or bifunctional glycoprotein conjugate, the compound comprising a carbohydrate complement, and:
 - a. at least one first portion which possesses enzymatic activity;
 - b. at least one second portion which binds specifically to an epitope of a tumor-specific antigen wherein said second portion is not an antibody or antibody fragment; wherein the carbohydrate complement comprises ~~at least one~~ an exposed terminal carbohydrate mannose residue and at least one exposed terminal carbohydrate residue selected from the group consisting of ~~mannose~~, galactose, N-acetylglucosamine, N-acetyllactose, glucose and fucose wherein said bifunctional fusion glycoprotein that has been synthesized in CHO cells, the cells having been selected for a high level of expression of the glycoprotein.
2. (Previously presented) The compound as claimed in claim 1, wherein the exposed carbohydrate residue is produced by enzymatic degradation.
3. (Previously presented) The compound according to claim 2, wherein the enzymatic degradation is effected by an enzyme selected from the group consisting of endoglycosidases, exoglycosidases, and neuraminidases, and a combination thereof.
4. (Previously presented) The compound according to claim 1, wherein the exposed carbohydrate residue is produced by chemical degradation.
5. (Previously presented) The compound according to claim 1 wherein the exposed carbohydrate residue is added to the compound by chemical means.

6. (Previously presented) The compound according to claim 1, wherein the first portion consists essentially of an enzyme.
7. (Currently amended) The compound according to claim 6, wherein the enzyme is selected from the group consisting of penicillin G amidase, penicillin V amidase, ~~beta~~- β -lactamase, alkaline phosphatase, carboxypeptidase G2, carboxypeptidase A, cytosine deaminase, nitroreductase, diaphorase, arylsulfatase, glycosidase, ~~beta~~- β -glucosidase, and ~~beta~~- β -glucuronidase.
8. (Canceled)
9. (Currently amended) The compound as claimed in claim 1, wherein the tumor cell marker to which the second portions binds comprises a tumor associated antigen selected from the group consisting of CEA, N-CAM, N-cadherin, PEM, GICA, TAG-72, TF.beta., GM3, GD3, GM2, GD2, GT3, HMWMAA, pMel17, gp113 (Muc18), p53, p97, MAGE-1, gp105, erbB2, EGF-R, PSA, transferrin-R, P-glycoprotein and cytokeratin.
- 10- 11. (Canceled)
12. (Previously presented) The compound according to claim 1, wherein the first portion and the second portion are connected by a linker molecule.
- 13-14. (Canceled)
15. (Currently amended) The compound according to claim 1, wherein the exposed terminal carbohydrate is residues comprise a galactose ~~or~~ and a mannose.
16. (Previously presented) A pharmaceutical preparation containing the compound according to claim 1 in a pharmaceutically acceptable vehicle.

17. (Previously presented) A pharmaceutical preparation containing the compound according to claim 1, and an agent capable of lowering the pH in a tumor to be treated, in a pharmaceutically acceptable vehicle.

18. (Previously presented) A pharmaceutical preparation, containing the compound according to claim 1, and galactose, in a pharmaceutically acceptable vehicle.

19-21. (Canceled)